The association of inheritance of different apolipoprotein E (APOE, gene; apoE, protein) alleles with the risk and rate of onset of Alzheimer's disease (AD) is now well established and widely confirmed. While there are now a collection of hypotheses concerning the specific relationship of APOE polymorphisms to various phenotypic manifestations of AD, no single compelling theory has been tested and universally accepted. The only clear fact emerging during the past 6 years is that differences in APOE genotype affect the average rate of disease onset as a predictable function of the inheritance of this polymorphic gene. Methods now exist to enable experimental designs to study the metabolic effects of inheriting different APOE alleles, addressing what differences that may be present for many years, perhaps over the entire lifetime, can lead to earlier or later manifestations of the disease and are therapeutically tractable. This review summarizes part of an experimental approach to identify biological pathways influenced by the different APOE polymorphisms that are relevant to the pathogenesis of AD. ß 2000 Published by Elsevier Science B.V.
Introduction
Is Alzheimer's disease (AD) something that develops late in life because certain neuropathological phenomena lead to neuronal degeneration, or does AD develop over many years because of a biased metabolism that leads to certain recognizable consequences? Are these hypotheses mutually exclusive? Hypothesis-driven research has favored some form of`something causes neurodegeneration' testing. For the past decade and a half, a circular argument has prevailed: one that states that since AD is diagnosed by the de¢ned presence of amyloid-containing plaques, alterations of amyloid precursor protein (APP) or the amyloid L-peptide (AL) metabolism must cause AD [1] . Similar phenotype/causality arguments can be made for formation of paired helical ¢laments from tau protein leading to neuro¢brillary tangles. The rapid pace of gene discovery for monogenic diseases has also emphasized this scienti¢c approach, usually generalizing the speculations to cover a broader estate of disease.
Susceptibility genes, like APOE (the apolipoprotein E gene) for AD, are not associated with full penetrance and have other associated environmental interactions. It is di¤cult to generalize about susceptibility genes, since APOE is still the only example of a susceptibility gene for AD that has been con¢rmed widely. There are numerous reports of other potential susceptibility polymorphisms in AD. None have been as broadly replicated as APOE, and other population-speci¢c e¡ects with these less common polymorphisms cannot be ruled out [2] . APOE polymorphisms have been associated with additional phenotypic or environmental phenomena, such as chronic and acute head injury, response to intracerebral hemorrhage and recovery from cardiopulmonary bypass surgery and stroke [3^11] . The fact that these environmental interactions may occur earlier in life and without any concurrent manifestations of AD pathology supports the notion that a lifelong biased metabolism may be present in the brain, depending on the inherited APOE genotype.
Current tools for pharmacogenomic analyses, including di¡erential gene expression, yeast two-hybrid interactions, proteomics and high resolution cell mapping, allow experimental designs that can simultaneously analyze multiple potential variants. In the past, such an approach could be termed`a ¢shing expedition'. Now, like other ¢shing expeditions, high performance, rapid, accurate and novel experiments can function like high resolution sonar detectors on real ¢shing trips. Whether or not a single hypothesis, or multiple simultaneous e¡ects, characterizes the pathogenesis of AD can now be subjected to pharmacogenomic methodologies.
The pharmaceutical industry has recently incorporated pharmacogenomic strategies aimed at detecting genetically relevant targets for high throughput drug screening. The fact that multiple metabolic pathways may be highlighted using a particular experimental approach simply allows the identi¢cation of multiple targets. The targets can be prioritized on the basis of expected side e¡ects, disease validity and chemical tractability to allow production of agonists or antagonists to be tested in experimental animals or man.
Biochemical background
ApoE is a lipid transport molecule that is a constituent of very low density lipoproteins, a subclass of high density lipoproteins and chylomicrons [12] . Cellular uptake of lipid complexes is mediated through the binding of lipid-complexed apoE to the low density lipoprotein (LDL) receptor and other related receptors [13] . APOE is located within an apolipoprotein gene family on human chromosome 19 and has three common alleles, designated O2, O3 and O4. These genetic variations result in amino acid substitutions (arginine or cysteine) at positions 112 and 158 of the protein [14] . In most Caucasian populations, APOE3/3 is the most common genotype and O3 is the most common allele; O4 and O2 are considered variants. ApoE4 has normal LDL receptor binding, but is associated with elevated plasma cholesterol and LDL levels. The apoE2 protein binds poorly to the LDL receptor, and APOE2/2 is the most common genotype associated with type III hyperlipoproteinemia [12] .
The largest amount of APOE mRNA is found in the liver; the second largest concentration, approximately one-third the level seen in liver, is in the brain [15, 16] . Brain apoE is synthesized locally, not by the liver, as shown in liver transplant patients, and is the major apolipoprotein in cerebrospinal £uid [17, 18] . Interesting models involving the storage and redistribution of cholesterol following peripheral and CNS injury were proposed about a decade ago [192 3] . Other functions of apoE in the nervous system, unrelated to lipid transport, have also been proposed. These include the possibility of it acting as a neurotrophic factor or modulator of neurotrophin activity, an antioxidant and a mediator of immune responses [24^31] . With regard to the pathophysiology of AD, the two most popular hypotheses concern amyloid plaques and neuro¢brillary tangles, the two pathological hallmarks of AD. In these hypotheses, apoE is thought to have an e¡ect on amyloid deposition or in the stabilization of microtubules [1,32^36] .
Genetic background
The original reports of the association of APOE4 with late-onset familial and sporadic AD were rapidly and widely con¢rmed throughout the world [374 7] . Later studies demonstrated that the O4 allele is also associated with sporadic early-onset AD and early-onset AD families without presenilin or APP mutations [48^52] . These multiple con¢rmations established the O4 allele as the most important genetic marker for risk of disease identi¢ed so far, accounting for approximately 50% of the genetic component of AD [53] . The association of APOE4 and AD in African-Americans and Hispanics remains controversial and may be absent in a very small sample of Nigerian AD cases and controls [54^57] .
The inheritance of each APOE4 allele is associated with an average earlier onset of disease of 6^8 years compared to inheritance of two APOE3 alleles [58] . Each APOE2 allele is associated with an additional 6^8 years later onset. Thus the mean onset for APOE4/4 homozygotes is less than 70 years of age, while APOE2/3 individuals have a mean onset greater than 90 years of age. It is important to note that these cumulative risk data are drawn from large population studies and cannot be applied to individuals curious about their risk for developing AD. For this reason, the use of APOE genetic testing as it relates to AD is speci¢cally restricted to patients suspected of having the disease. The cumulative risk data have been con¢rmed in multiple populations and predict the characteristics of AD in di¡erent groups [43,55,59^65] . In Japan, where the allele frequency of APOE4 is about half that in the USA, and where the APOE2 allele is also less frequent, most of the APOE4-associated AD patients have the APOE3/4 genotype [44, 47, 66, 67] . In the USA, 2^3% of the population have the APOE4/4 genotype, while in Japan it is less than 0.5%. Thus there are many fewer people with an average age of onset less than 70 years, and more with onset 76^78 years. There is also a lower frequency of AD in Japan. This conforms exactly with the long-standing clinical data from Japan: there is less AD and an older age of onset (76^78 years) [68] .
Thus the cumulative rate of AD development in a population is related to the type of APOE genotype inherited, independent of any mechanistic hypothesis. Can we design experiments that can assess the e¡ect of di¡erent APOE alleles on the metabolism of the brain while controlling for other variables? A secondary question is whether the data generated from experiments comparing brains expressing di¡er-ent human APOE alleles intersect with prevailing causative hypotheses and/or shed new and unexpected light on brain metabolic biases.
Experimental design
How can we model the metabolic di¡erences between brains inheriting human APOE4 alleles versus human APOE3 alleles and insure that the locations of APOE brain expression in the model re£ect that of human brain? Human brain expresses APOE mRNA in neurons as well as glia, distinguishing this expression pattern from rodents [69] . Human brain normally demonstrates particularly dense and complete immunostaining of astrocytic glial cells with intense immunoreactivity present within the thin rim of cytoplasm surrounding the nucleus but also in the processes as they spread throughout the neuropil and as they end on blood vessels. In contrast, neuronal immunoreactivity is less intense and con¢ned to the region of cytoplasm just around the nucleus and in proximal processes. There are two very distinct lines of allele-speci¢c, human APOEexpressing mice under the control of human or mouse promoters. The ¢rst line contains equal doses of genomic APOE transgenes on an APOE-de¢cient (`knock-out') background [70] . These animals have the natural human 5P and 3P human tissue expression elements present, and apoE localization mimics the human pattern with neuronal and glial expression. A second paradigm of human APOE`knock-in' mice also makes only human APOE mRNA, but does not have the natural human tissue expression elements present and does not express APOE in neurons unless a non-physiologic, neuron-speci¢c promoter is used [71^74] .
Human apoE protein isoforms can fully substitute for mouse apoE. Both the human genomic APOE mice and the human`knock-in' APOE mice live normal lifespans, and their phenotype can be distinguished only by neuronal and glial expression of apoE protein or mRNA, detected by immunostaining and in situ hybridization respectively. All of these mice have normal phenotypes, with the exception of subtle impairments in aged female mice with a rela-tively high copy number of human APOE transgenes arti¢cially driven by a neuronal-speci¢c promoter [71] . The experimental questions are whether di¡er-ences in the metabolism of the brains of APOE3 mice and APOE4 mice exist, and whether the experiments include neuronal metabolic biases that might be unique to the mice with neuronal expression of human APOE.
Review of gene expression technology to understand disease
The ability to measure and compare the levels at which genes are turned on in animal models or tissues represents a powerful method of identifying genes associated with diseases, traits and biological responses to chemicals. Existing methods for gene expression analysis fall into three groups: transcript sampling by direct DNA sequencing, transcript ampli¢cation and imaging, and hybridization-based approaches [75^89]. Serial analysis of gene expression, the most cost-e¡ective gene transcript-counting technique, produces short gene fragments that are concatenated and sequenced [85] . One can then compare the relative number of times each short sequence was recovered in di¡erent samples in order to determine if there was a di¡erence in gene expression. However, this technique is limited to those known genes for which the short fragments have already been sequenced. Transcript sequencing following subtractive hybridization, a method of physically removing the genes that are in common between two samples in order to identify a pool of gene di¡erences, also identi¢es di¡erentially expressed genes, but is limited to binary comparisons [90] . Transcript imaging approaches such as di¡erential display, partitioning by type IIS restriction enzymes, representational difference analysis and ampli¢ed fragment length polymorphism are rapid ways of fragmenting gene sequences and displaying them. The gene fragments can be visually formatted in order to compare and identify di¡erences in patterns that correspond to di¡erences in genes being turned on or o¡ [75,77, Fig. 1 . Hybridization-based di¡erential gene expression strategies. A diagram of Glaxo Wellcome's microarray approach of spotting sequences for known genes or pieces of genes on a ¢lter or microchip. Extracted RNA is radiolabeled using a reverse transcriptase (RT) PCR. The radiolabeled probes from a tissue of interest are allowed to anneal with the spotted genes to ¢nd their complementary sequences. When a gene from a tissue has found a match, the spot will`light up' by whatever detection technique (i.e., phosphoimaging, £uorescence, etc.) is employed. By comparing the patterns of di¡erent samples, one can deduce which genes are up and down regulated in which samples. 79, 80] . However, each of these techniques requires a time-consuming cloning and con¢rmation process for determining the identity of di¡erentially expressed gene fragments.
The recent development of microarrays has signi¢-cantly enhanced the capacity of hybridization techniques to identify di¡erences in gene expression [76,82^84] . Fig. 1 diagrams a microarray approach of spotting sequences for known genes or pieces of genes on a ¢lter or microchip and allowing the gene transcripts from a tissue of interest to anneal with the spotted genes to ¢nd their complementary sequences. When a gene from a tissue has found a match, the spot will`light up' by whatever detection technique (i.e., phosphoimaging, £uorescence, etc.) is employed. By comparing the patterns of di¡erent samples, one can deduce which genes are turned on and o¡ in which samples. A practical limitation of hybridization methods is that appropriate cDNA libraries need to be available.
Another approach to gene expression analysis uses the gene fragmentation strategy of di¡erential display in order to measure the abundance of known and novel genes. In addition, the strategy takes advantage of the known gene sequence databases in order to predict rapidly the identity of a gene fragment if the gene from which it is derived is already known. This approach is illustrated in Fig. 2 . Identi¢cation of gene fragments is achieved by treating samples with restriction enzymes, which cut DNA speci¢cally and reproducibly in certain regions, followed by PCR ampli¢cation. These ampli¢ed fragments are then sized and di¡erences in pattern or intensity are identi¢ed. The DNA fragments that are di¡erent are electronically searched in a database of known genes by length and the enzymes used in order to identify the gene as a known gene in the database or as a new gene not in the database. The new genes are then sequenced, and the known genes can be studied further immediately.
Hybridization-and gene fragmentation-based techniques complement each other by their ability to optimally detect expression variations of medium to high versus low message copy number. Hybridization-based methods are considered`closed' systems, with data generation depending on the depth and quality of the spotted cDNA library. Hybridization approaches are especially useful for detecting di¡er-ences of abundant to medium expressed messages. Gene fragmentation and sequencing strategies, on the other hand, are`open' systems that potentially detect all di¡erences in gene expression within an experimental system. These techniques are particularly useful in detecting di¡erences in rare and low copy number messages. It is possible that expression di¡erences of the higher copy number genes will be obscured due to the ampli¢cation step, which could be non-linear at high expression levels. Both the closed and open systems detect novel sequences; however, detection in the closed systems is dependent on representation on the cDNA grid.
These methods of di¡erential gene expression are readily applicable to animal models such as transgenics. In such a model, a mutant gene may be put into a mouse that may result in a phenotype or disease, and the genes that respond to the presence of the mutant gene by being turned up or down can be readily identi¢ed. These changes re£ect the transgenic animal's adaptation to the altered gene, not just a direct result of the transgenic change. In this type of study, the proteins encoded by these genes often cluster into biochemical or signal transduction pathways, o¡ering either elucidation of the disease mechanism(s) or generation of testable hypotheses. These animal gene markers, once con¢rmed by other complementary means, can be very valuable because some of them might be excellent targets for small molecule intervention as therapeutics. As an extension of gene identi¢cation and con¢rmation in a transgenic model, the human versions of these genes may be useful in diagnosing disease at an early stage or evaluating the response to drug therapy. Genetic variations within these genes may correlate with individuals that respond or are resistant to certain therapies. The use of tests for gene expression and DNA polymorphisms to triage drug therapy is an emerging science known as pharmacogenomics. Fig. 3 . An experimental design for identifying altered gene expression in APOE transgenic animals. Age-related and APOE allele-speci¢c alterations in patterns of gene expression can be studied using di¡erential gene expression studies. This schematic depicts one type of comparison using the gene fragmentation-based approach, GeneCalling. Gene expression patterns are compared in both young and old transgenic mice, genetically the same except for bearing human genomic fragments that encode APOE4 or APOE3. Three animals for each comparison point are examined; the bioinformatics of the system allows the noise due to inter-individual variations to be subtracted so that when APOE4 and APOE3 brains are compared, di¡erences based only on the APOE alleles can be analyzed.
Pharmacogenomic data analyses
When using inbred mice with the same genetic background except for bearing genomic fragments di¡ering only in whether APOE3 or APOE4 is coded, the comparison of otherwise normal brains would not be expected to demonstrate large di¡er-ences. The human apoE proteins would be expected to substitute for all observable mouse functions. By comparing brains of individual APOE3 or APOE4 animals with others carrying the same allele, one can measure the noise in a particular pharmacogenomic system. Fig. 3 illustrates a comparison of three mRNA preparations from three sibling animals with a single form of human APOE in the gene fragmentation strategy. The bioinformatics of the system allows the noise to be subtracted out so that when APOE4 and APOE3 brains are compared, di¡erences based only on the APOE genetic di¡erences can be displayed. As an extension, gene expression di¡eren-ces attributable to neuronal expression of human APOE can be identi¢ed by comparing the APOE genomic fragment transgenic mice with APOE-targeted replacement mice, which have human APOE under the in£uence of the natural murine APOE promoter. Furthermore, these comparisons can be allelespeci¢c. In light of APOE's role in recovery from brain stresses, di¡erences in gene expression of transgenic animals exposed to speci¢c challenges such as middle cerebral occlusion, a model of stroke injury, or experimentally induced head injury can also be performed.
While the data from such APOE experiments are not ready to be disclosed and illustrated, Fig. 4 illustrates the pathway information of a hypothetical experiment comparing normal and disease tissues. Identi¢cation of the subtracted peaks provides a surprisingly robust measurement of speci¢c gene expression di¡erences. Interpretation of these di¡erences can be illustrated in a convenient format by software that automatically allows metabolic pathways to be illustrated.
Similarly, comparisons of proteins that interact with each other, measured by high throughput yeast two-hybrid experiments, can be illustrated with similar informatics. Proteomic data can also be placed Fig. 4 . General experimental design and outcome in a gene fragmentation-based strategy. The expressed genes in a`normal' versus à diseased' tissue can be isolated, ampli¢ed by PCR and digested with a mixture of restriction endonucleases. These ampli¢ed fragments are then sized by gel electrophoresis, and di¡erences in pattern or intensity are identi¢ed. The DNA fragments that are di¡erent are electronically searched in a database of known genes by length and the enzymes used in order to identify the gene as a known gene in the database or as a new gene not in the database.
within the system, correlating expression of proteins in the same tissues. Of course, when suitably entered and collected in the same bioinformatic systems, synthesis of overlapping metabolic ¢elds can be readily identi¢ed.
Integrated bioinformatic systems that incorporate reproducible functional genomic databases can be analyzed, with comparisons available in silico because of the de¢ned genetic variables. Di¡erences in gene expression as a function of the ages of the animal, gender di¡erences or pharmacological treatments can all be encompassed by model-integrated, biotechnical systems. The practical problems are experimental design, cost and scale and, therefore, the pharmacogenomic approaches are probably only available in large, committed RpD organizations.
Pharmaceutical targets
Assume that the di¡erential gene experiments and associated proteomics identi¢ed three metabolic pathways that were di¡erentially expressed in APOE3 versus APOE4 animals. They could re£ect either of two general types: expected results, based on prior hypotheses in the literature, or unexpected results. In either case, they share the common feature of being metabolic enzymes and therefore are generally tractable for drug development.
Rate-limiting enzymes from each of the three pathways can be adapted to high throughput screens for the identi¢cation of agonist or antagonist compound lead series, which then may be selected as a possible therapy. The decision does not matter, only the experimental plan to perform the next series of experiments.
Suppose we have an agonist series and an antagonist series developed from the di¡erential metabolism of APOE4 and APOE3 brains. A possible secondary screen would be to observe whether the agonists or antagonists alter amyloid production in a tissue culture model. This type of secondary screen is relatively low cost, high throughput and rapid. A later screen could be to observe whether amyloid formation occurs earlier in the agonist-or antagonist-treated animals. Clearly the therapeutic product might then be sought in the series that delayed amyloid plaque formation. There are certainly other screens that could be applied. The point is that it does not really matter whether the investigator's personal belief system is that amyloid causes AD, or that it is a manifestation of an altered metabolism. A molecular series based on the di¡erences between APOE4 and APOE3 brains that delayed or halted amyloid deposition might be a very attractive potential lead for developing a drug to prevent AD. An old-fashioned ¢shing expedition using state-of-theart ¢sh ¢nding technology!
Conclusion
We are entering into a new era of drug discovery in which genetics and genomics will play a major role in target selection. Tractable targets for diseases with a huge unmet need, like AD, will soon be a reality. Combined with the use of targeted pharmacogenetic experiments in the drug development process, we will have new, innovative and e¡ective drugs. We will also be able to limit adverse events and decrease the cost of drug development with smaller numbers of patients and a higher proportion of responders based on pharmacogenetic pro¢les.
